Trial Profile
An open-label phase II study evaluating the safety and efficacy of PTK787/ZK222584 [vatalanib] in patients with metastatic neuroendocrine tumors that have evidence of progressive disease or an increase in disease related syndrome symptoms.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2011
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Biomarker; Therapeutic Use
- 28 Jun 2011 Actual initiation date changed from Dec 2006 to Nov 2004 as reported by ClinicalTrials.gov.
- 28 Jun 2011 Actual initiation date changed from Dec 2006 to Nov 2004 as reported by ClinicalTrials.gov.
- 02 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.